Cellectis

Société Anonyme
Traded as NASDAQ: CLLS Allternext:ACLS.PA
Industry Biotechnology, genome engineering, oncology
Founded 1999
Headquarters Paris XIIIème (France), New York (New York) United States
Key people
 André Choulika, David Sourdive
Products Engineered CAR T-Cells, TALEN® technology
Number of employees
 Approximately 105 Worldwide
Website www.cellectis.com

Cellectis a biopharmaceutical company focused on developing immunotherapies based on genome-edited CAR T-cells (UCARTs). Cellectis has been working in the gene editing field for 16 years to design novel products, particularly immune therapies for cancer.


History

Cellectis was founded by André Choulika in 1999 through a licensing agreement with the Pasteur Institute. In 2005, scientists working at Cellectis showed that meganucleases could be used to edit a genome in vivo[1]. Subsequent work led to refinements in the use of precision nucleases, particularly transcription activator-like (TAL) effector nucleases (TALEN®). In 2011, Cellectis acquired an exclusive license for the commercial application of TALEN® technology from the University of Minnesota and began researching the use of TALEN® to develop engineered immune cell therapies.

Cellectis has been trading on Alternext since 2007 and held an initial public offering on the NASDAQ exchange in March 2015[2].

Product Areas and Technologies

Cancer Immunotherapy

The company's portfolio includes several lines of proprietary chimeric antigen receptor (CAR) T cells targeting individual cancers. In 2014, Cellectis entered into strategic alliances with Servier and Pfizer to develop and commercialize "universal" CAR T-cells (UCARTs) targeting specific cancers. As of January 2016, Cellectis has five disclosed UCART products that are in various stages of clinical development.

In November 2015, Cellectis announced the first clinical use of its UCART technology. After she failed to respond to a traditional anti-cancer regimen, an 11-month old baby suffering from CD19+ acute lymphoblastic leukemia was treated at the Great Ormond Street Hospital with genome-edited donor T cells that had been engineered to attack leukemia cells. These cells had also been modified to be resistant to Alemtuzumab and to evade detection by the host immune system after introduction. A few weeks after therapy, the patient's condition improved, and the patient has been in remission for several months following treatment.[3] This compassionate case provides encouraging proof of concept for future clinical trials of T cell-based immunotherapies.

Engineered Nucleases

Cellectis is a leader in the use of precision genome editing technologies, including meganucleases, TAL effector nucleases (TALEN®), and "megaTALs," which combine the benefits of both meganucleases and TALEN constructs. The use of these technologies allows for predictable and accurate gene editing.

TALEN is believed to be the most effective tool today for therapeutic gene editing. Typical knockout efficiencies range from 85% to 90% for a single allele knockout, while preserving good functionality and viability.[4]

Pulse Agile

Cellectis uses proprietary electroporation technology to incorporate desired mRNA and DNA molecules into cells. This approach allows high transfection efficiency and preserves cell viability.

Plant Subsidiary Calyxt

Calyxt (formerly Cellectis Plant Sciences) was founded in 2010 in New Brighton, Minnesota. Calyxt aims to develop crops with improved nutritional and agricultural characteristics[5].

Publications

A complete list of publications is available on the company's website.[6]

References

  1. ↑ "history | cellectis". www.cellectis.com. Retrieved 2016-01-14.
  2. ↑ "Cellectis - January 2016 Corporate Presentation" (PDF). Cellectis S.A. Retrieved 2016-01-13.
  3. ↑ "Paper: First Clinical Application of Talen Engineered Universal CAR19 T Cells in B-ALL". ash.confex.com. Retrieved 2016-01-28.
  4. ↑ Phaciliate Limited. "Interview with David Sourdive, Executive Vice President of Corporate Development, Cellectis". Retrieved 28 January 2016.
  5. ↑ "Mission | Calyxt". www.calyxt.com. Retrieved 2016-01-15.
  6. ↑ "Scientific Publications | Cellectis". www.cellectis.com. Retrieved 2016-01-14.

External links

Category:biotechnology companies

This article is issued from Wikipedia - version of the Friday, February 05, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.